Wayne Fujita, MD
Dermatology · Aiea, HINPI 1073690152
Payments from drug & device makers
Across 1,652 payments — averaging $233.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$79K
- AbbVie$77K
- Amgen$74K
- E.r. Squibb & Sons, L.L.C.$32K
- Galderma Laboratories, L.p.$28K
- Bristol Myers Squibb$26K
- plus $68K from 27 others
What the payments were for
- Consulting fees$69,91418%
- Speaking & faculty fees$241,95563%
- Travel & lodging$29,1938%
- Food & beverage$43,22011%
- Education$9350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 101 | $78,524 |
| AbbVie | 274 | $77,175 |
| Amgen | 157 | $74,196 |
| E.r. Squibb & Sons, L.L.C. | 118 | $32,433 |
| Galderma Laboratories, L.p. | 116 | $28,492 |
| Bristol Myers Squibb | 34 | $26,156 |
| LEO Pharma Inc. | 131 | $21,376 |
| Sun Pharmaceutical Industries Inc. | 76 | $16,254 |
| Dermira, Inc. | 17 | $4,673 |
| UCB, Inc. | 45 | $4,280 |
| Sanofi | 80 | $3,825 |
| Regeneron Healthcare Solutions, Inc. | 80 | $3,349 |
| Galderma Research & Development, LLC | 1 | $2,975 |
| Arcutis Biotherapeutics, Inc. | 83 | $2,202 |
| Lilly USA, LLC | 86 | $2,141 |
| Novartis | 58 | $1,563 |
| Incyte Corporation | 51 | $1,530 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 47 | $1,330 |
| Johnson & Johnson | 44 | $951 |
| Dermavant Sciences, Inc. | 17 | $610 |
| Sanofi-aventis U.S. LLC | 9 | $331 |
| Organon | 12 | $273 |
| Regeneron | 1 | $161 |
| EPI Health, LLC | 1 | $95 |
| Almirall LLC | 2 | $78 |
| Genentech USA, Inc. | 2 | $44 |
| Journey Medical Corporation | 1 | $39 |
| Mylan Pharmaceuticals Inc. | 2 | $38 |
| Aclaris Therapeutics, Inc. | 2 | $34 |
| ANI Pharmaceuticals, Inc. | 1 | $31 |
| Revance Therapeutics, Inc. | 1 | $25 |
| VYNE Pharmaceuticals Inc. | 1 | $19 |
| Merck | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$385,218 in reported general payments places this provider in the 95th percentile of 67 dermatology providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 51 | $189,988 |
| OtezlaApremilast | 12 | $58,277 |
| OpzeluraRuxolitinib Phosphate | 22 | $44,233 |
| Tacrolimus | 130 | $36,540 |
| VtamaTapinarof | 11 | $15,344 |
| Tazarotene | 34 | $7,930 |
| Ammonium Lactate | 398 | $6,775 |
| Tretinoin | 66 | $4,781 |
| Fluocinonide | 63 | $3,837 |
| Ketoconazole | 293 | $3,524 |
| Fluorouracil | 56 | $2,917 |
| Fluocinonide-EFluocinonide/Emollient Base | 41 | $2,621 |
| Calcipotriene | 12 | $2,544 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 83 | $2,164 |
| Imiquimod | 56 | $1,698 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $74,196 | $58,27712 claims |
| Incyte CorporationOpzelura | $1,530 | $44,23322 claims |
| Dermavant Sciences, Inc.Vtama | $610 | $15,34411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 67 dermatology providers in Hawaii.
Other dermatology in Aiea
- William WongAiea$12K
- Emily WongAiea$2K
- Jenifer FongAiea$998
- Mika YamazakiAiea$162
- George MartinKihei$2M
- Douglas JohnsonHonolulu$704K
- Sarah HowellHonolulu$653K
- Monica ScheelKailua Kona$253K
- Ryan SatoHonolulu$226K
- Rebecca LuriaKailua$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.